Mesothelioma articles within Nature Communications

Featured

  • Article
    | Open Access

    Malignant pleural mesothelioma is an aggressive cancer with a poor prognosis and limited therapeutic options. Here the authors report the immunopeptidomic landscape of murine and human mesothelioma tumors and demonstrate the anti-tumor potential of oncolytic adenoviruses coated with so-defined tumor-specific peptides in a mouse model of mesothelioma.

    • Jacopo Chiaro
    • , Gabriella Antignani
    •  & Vincenzo Cerullo

  • Article
    | Open Access

    Malignant pleural mesothelioma (MPM) is an aggressive malignancy with few effective treatment options available. Here, the authors use dynamic BH3 profiling to measure drug-induced mitochondrial priming and identify AZD8055 and navitoclax as a pro-apoptotic drug combination in ex vivo and preclinical MPM models.

    • Danielle S. Potter
    • , Ruochen Du
    •  & Anthony Letai

  • Article
    | Open Access

    The mesothelium supports homeostasis and regeneration, yet its development origins remain unclear. Here, the authors uncovered the earliest mesothelium progenitor cells in zebrafish, linking Hand2 gene function to mesothelium formation and its re-activation to mesothelioma tumors.

    • Karin D. Prummel
    • , Helena L. Crowell
    •  & Christian Mosimann

  • Article
    | Open Access

    Treating malignant pleural mesothelioma (MpM) is challenging due to a lack of druggable genes, but other molecular features could be clinically useful. Here the authors profile mRNA translation dysregulation in MpM cell lines using polysome profiling, and identify mTORC1 and 2 as potential pharmacological targets.

    • Stefano Grosso
    • , Alberto Marini
    •  & Anne E. Willis

  • Comment
    | Open Access

    Delineation of the genomic complexities of malignant pleural mesothelioma (MPM) has lagged behind other malignancies. Zhang et al. meaningfully add to our understanding of MPM, and their findings emphasize the need to combine drug development efforts with appropriate predictive biomarkers.

    • Marjorie G. Zauderer

  • Article
    | Open Access

    The impact of intratumour heterogeneity on immune surveillance and clinical outcomes has not been adequately explored in malignant pleural mesothelioma (MPM). Here the authors analyse the influence of evolution on the survival and immune landscape of MPM patients using multi-region sequencing data.

    • Min Zhang
    • , Jin-Li Luo
    •  & Dean A. Fennell

  • Article
    | Open Access

    Additional sex combs-like (ASXLs) stimulate BAP1 deubiquitinase activity to induce tumor suppression, but how these complexes work in coordination in vivo is unclear. Here, the authors show the mutually reinforcing roles of BAP1 and ASXLs such that BAP1 promotes DEUBAD monoubiquitination of ASXL2, which in turn stimulates BAP1 DUB activity.

    • Salima Daou
    • , Haithem Barbour
    •  & El Bachir Affar

  • Article
    | Open Access

    Malignant pleural effusion (MPE) is a lethal condition associated with various cancers. Here, the authors show that cancer cells withKRASmutations promote MPE by recruiting myeloid cells via CCL2 signalling and that pharmaceutical targeting of KRAS results in reduced MPE incidence and volume in mouse models.

    • Theodora Agalioti
    • , Anastasios D. Giannou
    •  & Georgios T. Stathopoulos

Browse broader subjects

Browse Mesothelioma across other nature.com journals